Patents by Inventor DUKE UNIVERSITY

DUKE UNIVERSITY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130218239
    Abstract: Systems and methods for stimulation of neurological tissue and generation stimulation trains with temporal patterns of stimulation, in which the interval between electrical pulses (the inter-pulse intervals) changes or varies over time. The features of the stimulation trains may be selected and arranged algorithmically to by clinical trial. These stimulation trains are generated to target a specific neurological disorder, by arranging sets of features which reduce symptoms of that neurological disorder into a pattern which is effective at reducing those symptoms while maintaining or reducing power consumption versus regular stimulation signals. Compared to conventional continuous, high rate pulse trains having regular (i.e., constant) inter-pulse intervals, the non-regular (i.e., not constant) pulse patterns or trains that embody features of the invention provide increased efficacy and/or a lower than average frequency.
    Type: Application
    Filed: October 11, 2012
    Publication date: August 22, 2013
    Applicant: DUKE UNIVERSITY
    Inventor: DUKE UNIVERSITY
  • Publication number: 20130210136
    Abstract: Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation comprises administering into the lungs as a gas a compound with an NO group which does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders comprises administering into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and/or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Treatment of patient in need of improved oxygenation, blood flow of and/or thinning of blood comprises providing in the patient a therapeutic amount of red blood cells loaded with nitrosylated hemoglobin. A method is directed to screening drugs that increase level of nitrosoglutathione in airway lining fluid.
    Type: Application
    Filed: March 21, 2013
    Publication date: August 15, 2013
    Applicant: DUKE UNIVERSITY
    Inventor: DUKE UNIVERSITY
  • Publication number: 20130178411
    Abstract: The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.
    Type: Application
    Filed: March 12, 2013
    Publication date: July 11, 2013
    Applicant: DUKE UNIVERSITY
    Inventor: DUKE UNIVERSITY
  • Publication number: 20130177576
    Abstract: The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides, that when administered disrupt TrkB-mediated activation of PLC?1 phosphorylation. The invention further provides method of treatment comprising administering inhibitors of TrkB-mediated activation of PLC?1 phosphorylation alone or in combination with other pharmaceutical compositions to prevent or ameliorate nervous system disorders such as epilepsy, stroke, anxiety, migraine, and pain.
    Type: Application
    Filed: March 7, 2013
    Publication date: July 11, 2013
    Applicant: DUKE UNIVERSITY
    Inventor: DUKE UNIVERSITY
  • Publication number: 20130172274
    Abstract: Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.
    Type: Application
    Filed: March 12, 2013
    Publication date: July 4, 2013
    Applicant: DUKE UNIVERSITY
    Inventor: DUKE UNIVERSITY
  • Publication number: 20130143771
    Abstract: An article such as a biosensor having a nonfouling surface thereon is described. The article comprises: (a) a substrate having a surface portion; (b) a linking layer on the surface portion; (c) a polymer layer comprising brush molecules formed on the linking layer; and (d) optionally but preferably, a first member of a specific binding pair (e.g., a protein, peptide, antibody, nucleic acid, etc.) coupled to the brush molecules. The polymer layer is preferably formed by the process of surface-initiated polymerization (SIP) of monomeric units thereon. Preferably, each of the monomeric units comprises a monomer (for example, a vinyl monomer) core group having at least one protein-resistant head group coupled thereto, to thereby form the brush molecule on the surface portion. Methods of using the articles are also described.
    Type: Application
    Filed: January 3, 2013
    Publication date: June 6, 2013
    Applicant: DUKE UNIVERSITY
    Inventor: DUKE UNIVERSITY
  • Publication number: 20130060005
    Abstract: The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface.
    Type: Application
    Filed: November 5, 2012
    Publication date: March 7, 2013
    Applicants: TRUSTEES OF DARTMOUTH COLLEGE, DUKE UNIVERSITY, CHARITE-UNIVERSITAETSMEDIZIN BERLIN
    Inventors: TRUSTEES OF DARTMOUTH COLLEGE, CHARITE-UNIVERSITAETSMEDIZIN BERLIN, DUKE UNIVERSITY